Fennec Pharmaceuticals Inc. filings document formal disclosures for its commercial specialty pharmaceutical business, PEDMARK® product updates, and Nasdaq-listed common shares. Recent Form 8-K reports cover financial results, scientific presentations and investigator-sponsored studies involving sodium thiosulfate injection, and a license agreement resolving litigation tied to a proposed generic version of PEDMARK.
The company’s proxy materials cover director elections, board composition, executive compensation, equity awards, and shareholder voting matters. Other current reports disclose governance changes, registered common shares with no par value, and exhibits furnished with press releases concerning business, clinical, and product-related developments.
FENNEC PHARMACEUTICALS INC. Chief Strategy Officer Christiana Marie Cioffi reported a small share award under the company’s equity compensation. On May 31, 2026, she acquired 156 common shares at $0.00 per share, representing shares released from restriction from an award granted on March 28, 2025. Following this vesting-related acquisition, she directly holds 24,176 common shares, indicating a routine, compensation-driven increase in her ownership rather than an open-market purchase or sale.
FENNEC PHARMACEUTICALS INC. Chief Commercial Officer Terry L. Evans reported a compensation-related stock event. On May 31, 2026, Evans acquired 168 Common Shares at a stated price of $0.00 per share, characterized as a grant, award, or similar acquisition.
According to the filing, these shares represent a release from restriction on shares originally awarded on March 28, 2025. Following this transaction, Evans directly holds a total of 21,015 Common Shares of Fennec Pharmaceuticals, reflecting a routine increase in his equity-based compensation holdings rather than an open-market purchase or sale.
FENNEC PHARMACEUTICALS INC. Chief Medical Officer Sayad Pierre Sargis acquired 168 Common Shares through a grant classified as a “grant, award, or other acquisition.” The shares were released from restriction on equity originally awarded on 3/28/2025 and carried no purchase price.
Following this compensation-related acquisition, Sargis directly holds 21,015 Common Shares. The event reflects routine equity compensation rather than an open‑market share purchase or sale.
Fennec Pharmaceuticals Inc. reported that Chief Executive Officer Jeffrey S. Hackman acquired 1,159 Common Shares as a grant or award. The shares were released from restriction from an award originally granted on 3/28/2025 and carried a transaction price of $0.00 per share.
Following this compensation-related acquisition, Hackman directly owns 62,825 Common Shares. The filing reflects routine equity compensation rather than an open-market purchase or sale.
FENNEC PHARMACEUTICALS INC. reported that Chief Financial Officer Robert Andrade acquired 1,703 common shares as a grant or award on May 31, 2026. The shares were released from restrictions tied to prior awards dated May 16, 2024 and March 28, 2025, and carried no purchase price. After this vesting event, Andrade directly holds 289,269 common shares.
Fennec Pharmaceuticals Inc. reported that new research on PEDMARK® (sodium thiosulfate injection) will be presented at the 2026 American Society of Clinical Oncology Annual Meeting. Four independently led studies examine use of PEDMARK across pediatric, adolescent, young adult and adult patients receiving cisplatin-based chemotherapy.
Key data include a Japanese Phase 2/3 trial in 27 pediatric and adolescent patients where hearing loss rates of 16–24% with PEDMARK were lower than historically reported 56–63% with cisplatin alone, and real‑world series in young adults and adults with head and neck cancer suggesting feasible integration of PEDMARK several hours after cisplatin without compromising antitumor activity and with preservation of clinically significant hearing. The company also reiterates that PEDMARK is the first FDA‑approved therapy to reduce cisplatin‑related ototoxicity in pediatric patients with localized, non‑metastatic solid tumors.
Fennec Pharmaceuticals Inc. disclosed that its board’s Compensation Committee approved inducement stock option grants for three new non-executive employees. The awards cover an aggregate of 50,000 common shares under the 2026 Equity Inducement Plan as inducement grants pursuant to Nasdaq Listing Rule 5635(c)(4).
The stock options have an exercise price of $9.75 per share, a ten-year term, and vest over three years, with one-third vesting on the first anniversary of the May 18, 2026 grant date and the remainder vesting monthly over the following 24 months, subject to continued employment. A press release with further details was furnished as an exhibit.
FENNEC PHARMACEUTICALS INC. Schedule 13G/A (Amendment No. 3) reports that Solas Capital Management, LLC and Frederick Tucker Golden each hold 2,482,198 common shares, representing 7.2% of the class based on 34,475,178 shares outstanding as of March 20, 2026.
The filing states the reported holdings reflect shared voting and dispositive power of 2,482,198 shares and confirms the investment adviser/portfolio manager relationship; the Funds disclaim beneficial ownership pursuant to Rule 13d-4.
Fennec Pharmaceuticals Inc. reported strong quarterly growth as PEDMARK product sales, net, rose to $15.1 million for the three months ended March 31, 2026, up from $8.8 million a year earlier. Higher revenue helped the company swing from a net loss of $1.2 million in 2025 to net income of $0.2 million and positive operating cash flow of $2.4 million. Cash and cash equivalents increased to $40.2 million, with working capital of $57.3 million, and management believes this is sufficient to fund operations for at least twelve months. Fennec also highlighted its ex‑U.S. PEDMARQSI® license with Norgine, which included an upfront payment of about $43 million and potential milestones up to roughly $230 million, and a settlement with Cipla that delays U.S. generic sodium thiosulfate entry until September 1, 2033 under agreed terms.
FENNEC PHARMACEUTICALS INC. filing amends a Schedule 13G/A to report beneficial ownership stakes by Rosalind Advisors, Rosalind Master Fund L.P., Steven Salamon and Gilad Aharon. The filing states ownership percentages of 8.8% (Rosalind Advisors), 8.4% (Rosalind Master Fund), and 8.6% each for Steven Salamon and Gilad Aharon, based on 34,712,756 shares outstanding as of April 13, 2026.
The statement breaks down voting and dispositive powers: the Advisor and the Master Fund hold shared voting and disposition authority over 2,908,201 shares (reported in Item 4), while Mr. Salamon and Mr. Aharon individually report 66,666 shares of sole voting and dispositive power. The filing includes disclaimers from the Advisor and Mr. Salamon regarding beneficial ownership.